Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/27/2020 12:55:15 PM - Followers: 127 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 

Company website: 
http://www.aveooncology.com/

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

   





Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has approved on 8/28/17  FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)
 

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.

AV-353

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

 
www.aveopharma.com
Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  58%
20 Full Time Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: Current Report Filing (8-k) 02/19/2020 05:11:25 PM
AVEO News: AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split 02/19/2020 09:08:00 AM
AVEO News: Current Report Filing (8-k) 02/13/2020 04:35:19 PM
AVEO News: AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Jour... 02/12/2020 04:26:00 PM
AVEO News: AVEO Oncology & Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine & Nab-paclitaxel in Advanced Pancr... 01/27/2020 07:00:00 AM
PostSubject
#5457   Clays boys are shorting this to! They know. $$$$$ harry crumb 03/27/20 12:55:15 PM
#5456   Another long loser shows up, buy more we harry crumb 03/27/20 09:19:36 AM
#5455   Undoubtedly, you just like to see your name jaglag 03/26/20 07:19:33 PM
#5454   Undoubtedly, you just like to see your name jaglag 03/26/20 07:19:19 PM
#5453   Good luck on controlling the share price on BJ_Cooper 03/26/20 07:16:03 PM
#5452   * * $AVEO Video Chart 03-26-2020 * * ClayTrader 03/26/20 05:55:15 PM
#5451   Up $1.13!!! WTF Harry??? I thought this BJ_Cooper 03/26/20 02:39:29 PM
#5450   A sure tell tale sign this will fail: Not harry crumb 03/24/20 05:36:03 PM
#5449   Its coming, soon. Complete failures! harry crumb 03/24/20 12:44:41 PM
#5448   Yup harry crumb 03/24/20 12:44:16 PM
#5446   Bye bye aveo! Coming soon! harry crumb 03/22/20 09:29:58 PM
#5445   This week aveo may hit 1$! Will wait harry crumb 03/22/20 09:28:57 PM
#5442   Lmao, thats old news, an guess what pal, harry crumb 03/19/20 10:29:36 PM
#5441   just waiting for the NDA enthalpy 03/19/20 05:47:11 PM
#5440   Fotivda approved for 1st line RCC treatment in Denmark. Biotech Pharmer 03/19/20 03:28:04 PM
#5436   2$ friday folks, wealth made easy as i harry crumb 03/18/20 02:03:13 PM
#5434   Lol, scams inly steal your money, they dont harry crumb 03/18/20 10:48:49 AM
#5433   Only shares they attain are gonna be from harry crumb 03/18/20 10:47:52 AM
#5432   The end of tivo is near, OS failure harry crumb 03/18/20 10:45:42 AM
#5431   Under 3$, 2$ by end of the wek harry crumb 03/17/20 10:03:44 PM
#5430   Doesnt matter what baily posts, he is a harry crumb 03/17/20 12:10:57 PM
#5429   https://finance.yahoo.com/news/aveo-oncology-reports-full-2019-200500927.html Biotech Pharmer 03/16/20 05:21:13 PM
#5428   The end is coming for aveo! Fact! harry crumb 03/16/20 04:35:43 PM
#5427   If they meet the mile stones they will enthalpy 03/14/20 11:48:28 PM
#5426   I shorted the nasdaq big before ans sold Gungadin1 03/14/20 11:58:56 AM
#5425   if it's TRUE that AVEO cancer drug is enthalpy 03/14/20 10:56:25 AM
#5424   wow. check this out. a real possibility of enthalpy 03/14/20 10:34:49 AM
#5423   60 million from longs like you who do harry crumb 03/14/20 06:56:16 AM
#5422   Nah this company has 60 million in cash. enthalpy 03/13/20 08:37:06 PM
#5421   Buy "ino" corona vaccine will be worth 40+ harry crumb 03/13/20 08:30:48 PM
#5420   I dont believe anything on this boards. enthalpy 03/13/20 08:23:16 PM
#5417   you really think aveo really is working on enthalpy 03/13/20 07:35:39 PM
#5416   While I disagree with your political stance, I BJ_Cooper 03/13/20 06:42:05 PM
#5415   AVEO is days away from developing a coronavirus Biotech Pharmer 03/13/20 06:09:39 PM
#5414   There's toilet paper on your shoe Biotech Pharmer 03/13/20 02:29:52 PM
#5413   Lmoa! 2.50 already. From 6.00 down to 2.50! harry crumb 03/13/20 01:35:37 PM
#5412   Shorts are only the ones to wealth here! harry crumb 03/13/20 08:12:14 AM
#5411   Easy there my brainless rookie, facts are facts! harry crumb 03/13/20 08:11:42 AM
#5410   Dick....Head. I seriously hope you get cancer. What Biotech Pharmer 03/12/20 05:30:44 PM
#5409   This junk is down 50+ percent since the harry crumb 03/12/20 01:01:36 PM
#5408   2.00 next week! Lmao harry crumb 03/12/20 01:00:04 PM
#5407   Hope you sold! Lmao harry crumb 03/12/20 12:59:47 PM
#5406   US Steel down 10%, Boeing down 15%. Harry Biotech Pharmer 03/11/20 02:50:45 PM
#5405   5 days of silence from all of them, lmao harry crumb 03/11/20 01:46:30 PM
#5404   Luv how everyone finally disappeared, hopefully they saved harry crumb 03/11/20 01:11:04 PM
#5403   3$ end of week! Slam it! Junk,,should an harry crumb 03/11/20 07:51:26 AM
#5402   It has already list half its value from harry crumb 03/10/20 12:17:17 PM
#5401   Its not temporary, you need to understand before harry crumb 03/10/20 12:15:49 PM
#5399   Wheres all the longs?? In the basement lookn harry crumb 03/09/20 04:58:47 PM
#5398   Told everyone! This stock is only a short harry crumb 03/09/20 11:15:49 AM
PostSubject